TapImmune moves forward with new drugs

TapImmune Inc. is a pharmaceutical research company that may never make a big splash in Jacksonville, as far as local employment and operations go.However, the company is hoping to make an impact by proving the effectiveness of its cancer treatments under development. TapImmune describes itself as an “immune-oncology” company that is developing immunotherapies to treat…

Details

TapImmune Presents New Data at San Antonio Breast Cancer Symposium Showing Robust Generation of T-Cell Immunity

JACKSONVILLE, Florida, December 10, 2015 Vaccination with TPIV 100 boosts T-cell immunity to HER2 in HER2+ Breast Cancer Patients Provides catalyst to start Phase II studies TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today presented…

Details

TapImmune to Present New Data at San Antonio Breast Cancer Symposium on December 10, 2015

TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced its Chairman and CEO, Dr. Glynn Wilson, will be presenting new data at the 2015 San Antonio Breast Cancer Symposium, which will be held in San…

Details

Immuno-Oncology Company, TapImmune Inc., Moves Corporate Headquarters to Jacksonville Florida

Clinical-Stage Developer of Vaccines for Cancer & Metastatic Disease moves into closer proximity to collaborators at Mayo Clinic in Jacksonville JACKSONVILLE, Florida, November 5, 2015 /PRNewswire/ – TapImmune Inc., (TPIV) a clinical-stage immune-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, announced…

Details

TapImmune to Present at Dawson James Small Cap Growth Conference in Florida on October 15, 2015

JACKSONVILLE, Florida, October 13, 2015 /PRNewswire/ TapImmune, Inc. (TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, will be a featured presenting company at the Dawson James Small Cap Growth Conference at the Wyndham Grand Hotel in Jupiter, Florida…

Details

TapImmune to Present at Aegis Capital 2015 Growth Conference in Las Vegas on October 9, 2015

JACKSONVILLE, Florida, October 7, 2015 /PRNewswire/ – TapImmune, Inc. (TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, will be featured as a presenting company at the Aegis Capital Corp. 2015 Growth Conference, at the Encore Wynn Hotel in…

Details

National Breast Cancer Awareness Month

A personal perspective from Dr Glynn Wilson, Chairman & CEO, TapImmune National Breast Cancer Awareness Month (NBCAM), We start October on a high note. On September 15, TapImmune and the Mayo Clinic announced the award of a $13.3 million grant from the US Department of Defense Breast Cancer Research Program to Dr Keith Knutson and…

Details

TapImmune Vaccine to be Studied in a $13.3 Million U.S. Department of Defense Grant to Mayo Clinic for Phase II Clinical Trial in Triple Negative Breast Cancer

Trial will Utilize Folate Receptor Alpha Vaccine Licensed to TapImmune for Commercialization JACKSONVILLE, Florida, September 15, 2015 /PRNewswire/ – TapImmune, Inc. (TPIV), congratulates Mayo Clinic for being awarded a grant of $13.3 million from the U.S. Department of Defense. This grant, commencing September 15, 2015, will cover the costs for a 280 patient Phase II…

Details